Prime Medicine, Inc. (PRME)
3.89
+0.05
(+1.30%)
USD |
NASDAQ |
Nov 20, 10:00
Prime Medicine Cash from Operations (Quarterly) : -36.68M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -36.68M |
| June 30, 2026 | -41.05M |
| March 31, 2026 | -42.71M |
| December 31, 2025 | -37.26M |
| September 30, 2025 | -35.04M |
| June 30, 2025 | -41.41M |
| March 31, 2025 | -48.86M |
| December 31, 2024 | 16.24M |
| September 30, 2024 | -25.91M |
| June 30, 2024 | -45.49M |
| March 31, 2024 | -67.71M |
| December 31, 2023 | -43.86M |
| Date | Value |
|---|---|
| September 30, 2023 | -39.17M |
| June 30, 2023 | -40.82M |
| March 31, 2023 | -41.56M |
| December 31, 2022 | -30.71M |
| September 30, 2022 | -30.10M |
| June 30, 2022 | -20.22M |
| March 31, 2022 | -50.79M |
| December 31, 2021 | -13.19M |
| September 30, 2021 | -9.606M |
| June 30, 2021 | -6.412M |
| March 31, 2021 | -4.877M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | -85.43M |
| Beam Therapeutics, Inc. | -110.75M |
| Twist Bioscience Corp. | -0.173M |
| Moderna, Inc. | -1.559B |
| Q32 Bio, Inc. | -4.418M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 41.25M |
| Cash from Financing (Quarterly) | 2.868M |
| Free Cash Flow | -158.54M |
| Free Cash Flow Per Share (Quarterly) | -0.2079 |
| Free Cash Flow to Equity (Quarterly) | -34.92M |
| Free Cash Flow to Firm (Quarterly) | -36.98M |
| Free Cash Flow Yield | -22.47% |